Objectives To systematically review the efficacy and safety of TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Methods Databases including PubMed, EMbase, VIP, CNKI, WanFang Data and CBM were electronically searched from inception to December 2016 to collect randomized controlled trials (RCT) on TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 14 RCTs were included. The results of meta-analysis showed that: the complete remission rate (CR) (RR=1.73, 95%CI 1.35 to 2.22, P<0.000 1) and clinical efficacy rate (RR) (RR=1.31, 95%CI 1.22 to 1.42,P<0.000 01) of the TE group were superior to those of the CEF group. But there were no significant differences between two groups in cardiac toxicity, myelosuppression and gastrointestinal reactions. Conclusions TE regimen is superior to CEF regimen in terms of efficacy for the Chinese women with ⅡA to ⅢC stage breast cancer, and there is no difference between the incidence of adverse reactions. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.